Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Common Equity (2016 - 2025)

CV Sciences' Common Equity history spans 15 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 18.22% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 18.22% decrease, with the full-year FY2025 number at $1.5 million, down 18.22% from a year prior.
  • Common Equity hit $1.5 million in Q4 2025 for CV Sciences, down from $1.5 million in the prior quarter.
  • Over the last five years, Common Equity for CVSI hit a ceiling of $12.0 million in Q1 2021 and a floor of -$777000.0 in Q4 2022.
  • Historically, Common Equity has averaged $3.7 million across 5 years, with a median of $2.4 million in 2024.
  • Biggest five-year swings in Common Equity: plummeted 121.93% in 2022 and later surged 473.62% in 2023.
  • Tracing CVSI's Common Equity over 5 years: stood at $3.5 million in 2021, then plummeted by 121.93% to -$777000.0 in 2022, then surged by 473.62% to $2.9 million in 2023, then tumbled by 38.17% to $1.8 million in 2024, then fell by 18.22% to $1.5 million in 2025.
  • Business Quant data shows Common Equity for CVSI at $1.5 million in Q4 2025, $1.5 million in Q3 2025, and $1.8 million in Q2 2025.